Clinical Trial Update: Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updating the efficacy and safety of vunakizumab and ivarmacitinib in active Takayasu arteritis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Takayasu Arteritis

Drugs mentioned

• Ivarmacitinib
• Vunakizumab (Vunakizumab)

Snippet

Sponsor: Chinese SLE Treatment And Research Group | Conditions: Takayasu Arteritis (TAK) | Phase 4 | Status: NOT_YET_RECRUITING